Qwo (collagenase clostridium histolyticum-aaes), developed by Endo International plc (ENDP), was approved by the FDA on July 6, 2020, for the treatment of moderate-to-severe cellulite in the buttocks of adult women.Qwo is the first FDA-approved injectable treatment for cellulite, a harmless, dimpled appearance of the skin, affects mainly the buttocks and thighs of more than 80 percent of postpubertal women.Qwo is expected to be available in the United States starting in spring 2021.